| Database ID | Agent | Target | Cancer Type | Detail |
| DB00631 | bevacizumab | Vascular endothelial growth factor | Tumors of the nervous system | view |
| DB00632 | erlotinib | Epidermal growth factor receptor | Tumors of the nervous system | view |
| DB00633 | bevacizumab | Vascular endothelial growth factor | Tumors of the nervous system | view |
| DB00634 | bevacizumab | Vascular endothelial growth factor | Tumors of the nervous system | view |
| DB00635 | bevacizumab | Vascular endothelial growth factor | Tumors of the nervous system | view |
| DB00636 | bevacizumab | Vascular endothelial growth factor | non small cell lung cancer | view |
| DB00637 | bevacizumab | Vascular endothelial growth factor | advanced cancer with brain metastasis | view |
| DB00638 | bevacizumab | Vascular endothelial growth factor | advanced cancer with brain metastasis | view |
| DB00639 | icotinib | Epidermal growth factor receptor | advanced cancer with brain metastasis | view |
| DB00640 | icotinib | Epidermal growth factor receptor | advanced cancer with brain metastasis | view |
| DB00641 | dacomitinib | Epidermal growth factor receptor, Proto oncogene proteinc mdm2, Erbb2 tyrosine kinase receptor | head and neck cancer | view |
| DB00642 | erlotinib | Epidermal growth factor receptor | advanced cancer with brain metastasis | view |
| DB00643 | erlotinib | Epidermal growth factor receptor | advanced cancer with brain metastasis | view |
| DB00644 | gefitinib | Epidermal growth factor receptor | advanced cancer with brain metastasis | view |
| DB00645 | erlotinib | Epidermal growth factor receptor | advanced cancer with brain metastasis | view |